Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avanos Medical, Inc. filings document the regulatory record of a medical technology company with product portfolios in Specialty Nutrition Systems and Pain Management and Recovery. Current reports furnish operating results, segment performance, investor presentations, material definitive agreements, executive compensation actions and organizational restructuring disclosures.
Proxy materials describe annual meeting matters, board elections, governance practices and compensation programs. The filings also cover capital-structure disclosures, shareholder voting matters, product-portfolio descriptions for enteral feeding and non-opioid pain therapies, and formal exhibits tied to material events.
John Joseph Hurley, Principal Accounting Officer of Avanos Medical, Inc. (AVNS), reported a Form 4 disclosing a tax-withholding sale tied to vested restricted stock units. On 09/05/2025 the filing shows 345 shares were disposed of at $12.66 per share under transaction code F(1). The filing explains these shares were surrendered to the issuer to satisfy tax withholding on time-based restricted share units awarded on 09/05/2024. After the transaction, Hurley beneficially owns 11,364 shares directly. The Form 4 was signed by an attorney-in-fact on 09/09/2025.
Scott M. Galovan, SVP and Chief Financial Officer of Avanos Medical, reported beneficial ownership of 111,009 shares of common stock on Form 3 filed for the 08/01/2025 event. Of those shares, 80,718 are unvested time-based restricted share units that vest on scheduled dates through August 1, 2028. The filing also lists employee stock options totaling 26,582 underlying shares with varying exercise prices and vesting/exercise dates.
Gary Blackford, a director of Avanos Medical, Inc. (AVNS), reported purchases of a total of 60,000 shares on 08/13/2025 in two grouped transactions: 20,000 shares acquired at a weighted-average price of $10.975 and 40,000 shares acquired at a weighted-average price of $10.995.
Following these transactions the filing shows 91,593 shares beneficially owned directly and 40,000 shares held indirectly in trusts for immediate family members (the reporting person is co-trustee and disclaims beneficial ownership except to the extent of pecuniary interest). The Form 4 was signed by an attorney-in-fact on 08/15/2025.